Special Issue

Malignant Glioma: Novel Therapeutic Strategies

Message from the Guest Editors

Malignant gliomas are a group of hard-to-treat brain tumors. Glioblastoma is among the most aggressive forms of these primary brain tumors, and is associated for most patients with an overall survival of less than 18 months. This is despite an intensive treatment regime of maximal safe tumor resection, followed by radiotherapy and treatment with the alkylating agent temozolomide. While novel treatment strategies are obviously in dire need, glioma come with a unique set of difficulties that need to be overcome. Furthermore, glioblastoma cells have invariably spread throughout the brain upon presentation, necessitating a treatment approach that is brain systemic. In recent years novel promising treatment approaches have been put forward that take the specific features of gliomas into account. Pharmaceuticals invites both reviews and original articles shedding light on the challenges and opportunities specific to glioma. Topics include drug repurposing, the roles of the immune system and the tumor metabolism, as well as improving understanding of already implemented strategies. The collection of manuscripts will be published as a Special Issue of the journal.

Guest Editors

Dr. Mike-Andrew Westhoff

Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, 89081 Ulm, Germany

Dr. Georg Karpel-Massler

Department of Neurological Surgery, Ulm University | UULM, Ulm, Germany

Deadline for manuscript submissions

closed (30 January 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/47040

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

